Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sym024
- Development stage
- Phase 2
- Lead developer
- Symphogen
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sym024 is a human monoclonal antibody that targets CD73 (also known as 5'-nucleotidase or NT5E), an ectoenzyme involved in the production of immunosuppressive adenosine in the tumor microenvironment. By inhibiting CD73, Sym024 aims to reduce adenosine-mediated immune suppression and enhance antitumor immune responses. The drug is being developed primarily for advanced solid tumors and non-small cell lung cancer. It has been studied both as monotherapy and in combination with Sym021 (an anti-PD-1 antibody). Preclinical data suggest that combining CD73 inhibition with PD-1 blockade may synergistically reverse immune suppression and promote T cell activation. The developer is Symphogen (a subsidiary of Servier)[1][3][4][5][8].
- Other names
- anti-CD73 monoclonal antibody Sym024anti-CD-73 monoclonal antibody Sym024anti-CD 73 monoclonal antibody Sym024
02
Targets
NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on sym024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sym024.